| Issue Date | Title | Author(s) |
| 2016-10-11 | MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma. | Fabian, J; Opitz, D; Althoff, K; Lodrini, M; Hero, B; Volland, R; Beckers, A; de Preter, K; Decock, A; Patil, N; Abba, M; Kopp-Schneider, A; Astrahantseff, K; Wünschel, J; Pfeil, S; Ercu, M; Künkele, A; Hu, J; Thole, T; Schweizer, L; Mechtersheimer, G; Carter, D; Cheung, BB; Popanda, O; von Deimling, A; Koster, J; Versteeg, R; Schwab, M; Marshall, GM; Speleman, F; Erb, U; Zoeller, M; Allgayer, H; Simon, T; Fischer, M; Kulozik, AE; Eggert, A; Witt, O; Schulte, JH; Deubzer, HE |
| 2016-08-09 | A novel compound which sensitizes BRAF wild-type melanoma cells to vemurafenib in a TRIM16-dependent manner. | Sutton, SK; Carter, DR; Kim, P; Tan, O; Arndt, GM; Zhang, XD; Baell, J; Noll, BD; Wang, S; Kumar, N; McArthur, GA; Cheung, BB; Marshall, GM |
| 2016-06 | Glutathione biosynthesis is upregulated at the initiation of MYCN-driven neuroblastoma tumorigenesis. | Carter, DR; Sutton, SK; Pajic, M; Murray, J; Sekyere, EO; Fletcher, J; Beckers, A; De Preter, K; Speleman, F; George, RE; Haber, M; Norris, MD; Cheung, BB; Marshall, GM |
| 2021-03 | Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy. | Chen, J; Nelson, C; Wong, M; Tee, AE; Liu, PY; La, T; Fletcher, JI; Kamili, A; Mayoh, C; Bartenhagen, C; Trahair, TN; Xu, N; Jayatilleke, N; Wong, M; Peng, H; Atmadibrata, B; Cheung, BB; Lan, Q; Bryan, TM; Mestdagh, P; Vandesompele, J; Combaret, V; Boeva, V; Wang, JY; Janoueix-Lerosey, I; Cowley, MJ; MacKenzie, KL; Dolnikov, A; Li, J; Polly, P; Marshall, GM; Reddel, RR; Norris, MD; Haber, M; Fischer, M; Zhang, XD; Pickett, HA; Liu, T |
| 2019-11-01 | Drugging MYCN oncogenic signaling through the MYCN-PA2G4 binding interface | Koach, J; Holien, JK; Massudi, H; Carter, DR; Ciampa, OC; Herath, M; Lim, T; Seneviratne, JA; Milazzo, G; Murray, JE; McCarroll, JA; Liu, B; Mayoh, C; Keenan, B; Stevenson, BW; Gorman, MA; Bell, JL; Doughty, L; Hüttelmaier, S; Oberthuer, A; Fischer, M; Gifford, AJ; Liu, T; Zhang, X; Zhu, S; Gustafson, WC; Haber, M; Norris, MD; Fletcher, JI; Perini, G; Parker, MW; Cheung, BB; Marshall, GM |
| 2019-01-30 | Inhibition of polyamine synthesis and uptake reduces tumor progression and prolongs survival in mouse models of neuroblastoma | Gamble, LD; Purgato, S; Murray, J; Xiao, L; Yu, DMT; Hanssen, KM; Giorgi, FM; Carter, DR; Gifford, AJ; Valli, E; Milazzo, G; Kamili, A; Mayoh, C; Liu, B; Eden, G; Sarraf, S; Allan, S; Giacomo, SD; Flemming, CL; Russell, AJ; Cheung, BB; Oberthuer, A; London, WB; Fischer, M; Trahair, TN; Fletcher, JI; Marshall, GM; Ziegler, DS; Hogarty, MD; Burns, MR; Perini, G; Norris, MD; Haber, M |
| 2021-09-24 | MEIS2 Is an Adrenergic Core Regulatory Transcription Factor Involved in Early Initiation of TH-MYCN-Driven Neuroblastoma Formation. | De Wyn, J; Zimmerman, MW; Weichert-Leahey, N; Nunes, C; Cheung, BB; Abraham, BJ; Beckers, A; Volders, P-J; Decaesteker, B; Carter, DR; Look, AT; De Preter, K; Van Loocke, W; Marshall, GM; Durbin, AD; Speleman, F; Durinck, K |
| 2020-11-12 | Withaferin A activates TRIM16 for its anti-cancer activity in melanoma. | Nagy, Z; Cheung, BB; Tsang, W; Tan, O; Herath, M; Ciampa, OC; Shadma, F; Carter, DR; Marshall, GM |
| 2021-03-25 | An ALYREF-MYCN coactivator complex drives neuroblastoma tumorigenesis through effects on USP3 and MYCN stability | Nagy, Z; Seneviratne, JA; Kanikevich, M; Chang, W; Mayoh, C; Venkat, P; Du, Y; Jiang, C; Salib, A; Koach, J; Carter, DR; Mittra, R; Liu, T; Parker, MW; Cheung, BB; Marshall, GM |
| 2016-01-01 | The long noncoding RNA MALAT1 promotes tumor-driven angiogenesis by up-regulating pro-angiogenic gene expression | Tee, AE; Liu, B; Song, R; Li, J; Pasquier, E; Cheung, BB; Jiang, C; Marshall, GM; Haber, M; Norris, MD; Fletcher, JI; Dinger, ME; Liu, T |
